Skip to main content
Top
Published in: Discover Oncology 1/2024

Open Access 01-12-2024 | Pancreatic Cancer | Research

circ_WASF2 regulates ferroptosis by miR-634/ GPX4 signaling in pancreatic cancer

Authors: Tao Liu, Xing-ming Xie, Ya-peng He, Jia-yao Zhang, Jun-ying Mou

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Purpose

Pancreatic cancer (PC) is one of the most lethal malignant gastrointestinal tumors (GI) characterized by a poor prognosis. Ferroptosis is an emerging programmed cell death that plays an essential role in the progression of various cancers. Ferroptosis is driven by iron-dependent phospholipid peroxidation and is regulated by mitochondrial activity, lipid peroxidation, and reactive oxygen species (ROS). The function and mechanism of ferroptosis in PC need more research.

Methods

The levels of circRNAs, miRNAs, and mRNAs were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Western blot was used for protein detection. CCK8 assays were used to detect cell proliferation. Cell death, lipid peroxidation, ROS, and Fe2+ were detected by indicted kits. Dual-luciferase reporter and RNA pull-down assays were conducted to confirm the interaction between circRNAs, miRNAs, and mRNAs.

Results

In this research, we found that circular RNA hsa_circ_0000003(circ_WASF2) was upregulated in pancreatic cancer cells. The silence of circ_WASF2 inhibited cancer proliferation and increased cell death by increasing ferroptosis accompanied by up-regulation of lipid peroxidation, ROS, and Fe2+. Further studies showed that circ_WASF2 could attenuate ferroptosis by targeting miR-634 and the downstream glutathione peroxidase 4 (GPX4). GPX4 has been well-reported as a central factor in ferroptosis. Our research revealed a new pathway for regulating ferroptosis in PC.

Conclusion

In summary, we have determined that circ_WASF2/miR-634/GPX4 contributed to ferroptosis-induced cell death, and provided a possible therapeutic target in PC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Can Res. 2014;74:2913–21.CrossRef Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Can Res. 2014;74:2913–21.CrossRef
2.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
6.
go back to reference Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:597–612.CrossRefPubMed Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:597–612.CrossRefPubMed
8.
go back to reference Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma—a population-based cohort study. Acta Oncol. 2015;55:265–77.CrossRefPubMed Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma—a population-based cohort study. Acta Oncol. 2015;55:265–77.CrossRefPubMed
11.
go back to reference Li Z, Luo Y, Wang C, Han D, Sun W. Circular RNA circBLNK promotes osteosarcoma progression and inhibits ferroptosis in osteosarcoma cells by sponging miR-188–3p and regulating GPX4 expression. Oncol Rep. 2023;50:192.CrossRefPubMedPubMedCentral Li Z, Luo Y, Wang C, Han D, Sun W. Circular RNA circBLNK promotes osteosarcoma progression and inhibits ferroptosis in osteosarcoma cells by sponging miR-188–3p and regulating GPX4 expression. Oncol Rep. 2023;50:192.CrossRefPubMedPubMedCentral
13.
go back to reference Luo Y, Huang Q, He B, Liu Y, Huang S, Xiao J. Regulation of ferroptosis by noncoding RNAs in the development and treatment of cancer (review). Oncol Rep. 2021;45:29–48.CrossRefPubMed Luo Y, Huang Q, He B, Liu Y, Huang S, Xiao J. Regulation of ferroptosis by noncoding RNAs in the development and treatment of cancer (review). Oncol Rep. 2021;45:29–48.CrossRefPubMed
14.
go back to reference Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31.CrossRefPubMedPubMedCentral Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31.CrossRefPubMedPubMedCentral
16.
go back to reference Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285–96.CrossRefPubMed Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285–96.CrossRefPubMed
17.
go back to reference Zheng, H., Jiang, J., Xu, S., Liu, W., and Li, R. (2021). Nanoparticle induced ferroptosis: detection methods, mechanisms and applications. Nanoscale. Zheng, H., Jiang, J., Xu, S., Liu, W., and Li, R. (2021). Nanoparticle induced ferroptosis: detection methods, mechanisms and applications. Nanoscale.
18.
go back to reference Luka B, Metka RG, Damjan G. Circular RNAs: biogenesis, function, and a role as possible cancer biomarkers. Int J Genomics. 2017;2017:1–19.CrossRef Luka B, Metka RG, Damjan G. Circular RNAs: biogenesis, function, and a role as possible cancer biomarkers. Int J Genomics. 2017;2017:1–19.CrossRef
19.
go back to reference Wang HH, Ma JN, Zhan XR. Circular RNA Circ_0067934 attenuates ferroptosis of thyroid cancer cells by miR-545–3p/SLC7A11 signaling. Front Endocrinol. 2021;12:660. Wang HH, Ma JN, Zhan XR. Circular RNA Circ_0067934 attenuates ferroptosis of thyroid cancer cells by miR-545–3p/SLC7A11 signaling. Front Endocrinol. 2021;12:660.
20.
go back to reference Xiao Y. Construction of a circRNA-miRNA-mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma. J Cell Biochem. 2019;121:394–406.CrossRefPubMed Xiao Y. Construction of a circRNA-miRNA-mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma. J Cell Biochem. 2019;121:394–406.CrossRefPubMed
21.
go back to reference Mugoni V, Ciani Y, Nardella C, Demichelis F. Circulating RNAs in prostate cancer patients. Cancer Lett. 2021;524:57–69.CrossRefPubMed Mugoni V, Ciani Y, Nardella C, Demichelis F. Circulating RNAs in prostate cancer patients. Cancer Lett. 2021;524:57–69.CrossRefPubMed
22.
go back to reference Ahmed I, Azis TKA, Alazwani EK, Mohamoud YA, Rafii A, Malek J. Characterization of circular RNAs in ovarian cancer. 2014 Ahmed I, Azis TKA, Alazwani EK, Mohamoud YA, Rafii A, Malek J. Characterization of circular RNAs in ovarian cancer. 2014
23.
go back to reference Jin J, Chen A, Qiu W, Chen Y, Li Q, Zhou X, Jin D. Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136. J Cell Biochem. 2019;120:15678.CrossRefPubMed Jin J, Chen A, Qiu W, Chen Y, Li Q, Zhou X, Jin D. Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136. J Cell Biochem. 2019;120:15678.CrossRefPubMed
26.
go back to reference Niu L, Sun N, Kong L, Xu Y, Kang Y. miR-634 inhibits human vascular smooth muscle cell proliferation and migration in hypertension through Wnt4/-catenin pathway. Front Biosci-Landmark. 2021;26:395–404.CrossRef Niu L, Sun N, Kong L, Xu Y, Kang Y. miR-634 inhibits human vascular smooth muscle cell proliferation and migration in hypertension through Wnt4/-catenin pathway. Front Biosci-Landmark. 2021;26:395–404.CrossRef
27.
go back to reference Yang B, Kuai F, Chen Z, Fu D, Zhong J. miR-634 decreases the radioresistance of human breast cancer cells by targeting STAT3. Cancer Biother Radiopharm. 2020;35:241.PubMed Yang B, Kuai F, Chen Z, Fu D, Zhong J. miR-634 decreases the radioresistance of human breast cancer cells by targeting STAT3. Cancer Biother Radiopharm. 2020;35:241.PubMed
28.
go back to reference van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM, Verweij J, Wiemer EA. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer. 2015;14:196.CrossRefPubMedPubMedCentral van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM, Verweij J, Wiemer EA. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer. 2015;14:196.CrossRefPubMedPubMedCentral
29.
go back to reference Li Q, Li KC, Guo Q, Yang T. CircRNA circSTIL inhibits ferroptosis in colorectal cancer via miR-431/SLC7A11 axis. Environ Toxicol. 2023;38:981–9.CrossRefPubMed Li Q, Li KC, Guo Q, Yang T. CircRNA circSTIL inhibits ferroptosis in colorectal cancer via miR-431/SLC7A11 axis. Environ Toxicol. 2023;38:981–9.CrossRefPubMed
Metadata
Title
circ_WASF2 regulates ferroptosis by miR-634/ GPX4 signaling in pancreatic cancer
Authors
Tao Liu
Xing-ming Xie
Ya-peng He
Jia-yao Zhang
Jun-ying Mou
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-01001-4

Other articles of this Issue 1/2024

Discover Oncology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine